If your doctor has recommended a biologic for Crohn's disease, you likely have a lot of questions: What is a biologic? Which biologics are used for Crohn's? Should I take one? If so, when -- and which one?
WebMD answers these commonly asked questions about biologics and suggests some other questions to ask your doctor -- and yourself -- to help you choose the treatment that's right for you.
What Are Biologics?
Also known as biologic response modifiers or biologic agents, biologics are genetically engineered therapies made from living organisms. Unlike some other Crohn's medications, which suppress the entire immune system, the biologic agents target specific players in the inflammatory response. For that reason, they may avoid some of the broad side effects that come with some other drugs.
Biologics have been used for a little over a decade. Remicade (infliximab) was the first biologic approved to treat Crohn's, in 1998. Today, there are four biologics approved for Crohn's treatment.
Cimzia (certolizumab), Humira (adalimumab), and Remicade work by inhibiting a protein called tumor necrosis factor alpha that's involved in inflammation. Another medication, Tysabri (natalizumab), blocks certain types of white blood cells that are involved in inflammation.
Should I Take a Biologic? If So, When?
Whether or not you take a biologic will depend largely on how severe your Crohn's is, which other treatments you have tried, your doctor's treatment philosophy, and your preference.
Biologics are FDA approved for people with moderate to severe active disease who have not had an adequate response to traditional treatments.
Some doctors, including Marie Borum, MD, professor of medicine and director of the Division of Gastroenterology and Liver Diseases at George Washington University in Washington, D.C., use what is called step-up therapy. A doctor who uses this approach does not suggest a biologic until you have tried and failed conventional treatments such as aminosalicylates, antibiotics, or drugs that suppress the immune system such as methotrexate, says Borum.
There are several reasons for the step-up approach, she says. "[Non-biologic] therapies have been around long, so we are more familiar with them -- we know how they work, we know what to expect and, because of our comfort level with them, we tend use them first and hold the biologics," says Borum.
Also, she says if you use a biologic early on, you exhaust your treatment options up front. "After that, if you have an exacerbation you may well be in a situation where you no longer have options," Borum says.
Others doctors, including Richard Bloomfeld, MD, are more likely to prescribe biologics from the start in hopes that they can help people avoid complications and surgery.
"Although there are other drugs I often use, anti-TNF biologics should not be reserved as a last-ditch effort," says Bloomfeld, associate professor of medicine and director of the Inflammatory Bowel Disease Program at Wake Forest University School of Medicine in Winston Salem, N.C. "The trend is to use biologics early in the disease course with the hope of altering the history of disease."